iifl-logo-icon 1

Dr Reddys Laboratories Ltd Half Yearly Results

1,192.35
(-0.55%)
Feb 18, 2025|11:39:57 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2024Mar-2024Sept-2023Mar-2023Sept-2022

Gross Sales

15,688.8

14,297.8

13,618.6

13,066.8

11,521.1

Excise Duty

0

0

0

0

0

Net Sales

15,688.8

14,297.8

13,618.6

13,066.8

11,521.1

Other Operating Income

45.5

52.8

41.9

38.2

43.6

Other Income

486.7

411.5

497.5

186.6

905.9

Total Income

16,221

14,762.1

14,158

13,291.6

12,470.6

Total Expenditure

11,507.9

10,487.9

9,590.1

9,608.3

8,712.4

PBIDT

4,713.1

4,274.2

4,567.9

3,683.3

3,758.2

Interest

135.5

98.7

72.4

77.2

65.6

PBDT

4,577.6

4,175.5

4,495.5

3,606.1

3,692.6

Depreciation

777.6

741.2

728.8

639.2

611

Minority Interest Before NP

0

0

0

0

0

Tax

1,292.8

636.1

1,309.8

737.5

76.9

Deferred Tax

-227.1

107.5

-430.3

25.3

701.5

Reported Profit After Tax

2,734.3

2,690.7

2,887.2

2,204.1

2,303.2

Minority Interest After NP

86.2

0

0

0

0

Net Profit after Minority Interest

2,648.1

2,690.7

2,887.2

2,204.1

2,303.2

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

2,648.1

2,690.7

2,887.2

2,204.1

2,303.2

EPS (Unit Curr.)

159

161.31

173.64

132.3

138.77

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

83.4

83.4

83.4

83.3

83.2

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

30.04

29.89

33.54

28.18

32.62

PBDTM(%)

-

-

-

-

-

PATM(%)

17.42

18.81

21.2

16.86

19.99

Dr Reddys Labs: Related NEWS

Dr Reddy’s Laboratories Q3 net profit zooms ~3%
24 Jan 2025|10:23 AM

The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.

Read More
Top Stocks for Today - 24th January 2025
24 Jan 2025|07:50 AM

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

Read More
Top Stocks for today - 6th December 2024
6 Dec 2024|09:14 AM

Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.

Read More
Dr Reddy’s launches first immuno-onco drug in India
28 Nov 2024|03:43 PM

Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.

Read More
Dr Reddy’s Bollaram Facility Receives USFDA Form 483 with 7 Observations
21 Nov 2024|11:14 PM

Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.

Read More
Top Stocks for today - 21st November 2024
21 Nov 2024|07:53 AM

Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.

Read More
Dr Reddy’s posts 15% y-o-y decline in Q2 net profit at ₹1,255 Crore
6 Nov 2024|09:25 AM

EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.

Read More
Top stocks for today - 6th November 2024
6 Nov 2024|08:08 AM

Here are some of the stocks that may see significant price movement today: Dr Reddy’s, Hindustan Zinc, Titan Company, etc.

Read More
Top 10 stocks for today – 11th October, 2024
11 Oct 2024|08:56 AM

Here are some of the stocks that may see significant price movement today: Mazagon Dock Shipbuilders, Krsnaa Diagnostics, Dr Reddy's, etc.

Read More
Dr Reddy’s subsidiary gets positive outcome for CAR-T cell trial
9 Oct 2024|03:48 PM

The experiment also had a favourable safety profile, with no serious adverse effects such as Cytokine Release Syndrome (CRS) or neurotoxicity reported.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.